An interventional study of Individualized exercise program and Control Arm in Breast Cancer Female, sponsored by University of Michigan Rogel Cancer Center. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.
Sponsored by University of Michigan Rogel Cancer Center · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Breast Neoplasms by University of Michigan Rogel Cancer Center — 5 open to participants now, 8 under way, none of them phase 3. Breast Neoplasms · University of Michigan Rogel Cancer Center.
Among the 48 studies in Breast Neoplasms by University of Michigan Rogel Cancer Center, this one is the 7th largest by planned enrollment of the 36 interventional ones that give a count, is one of 5 that started in 2024, is one of 18 with no phase, and was the 43rd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →5 of the 48 studies in Breast Neoplasms by University of Michigan Rogel Cancer Center are open now, in 1 country. Recruiting first, the newest first:
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+ · Women only
University of Michigan Rogel Cancer Center · Sites in United States
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+ · Women only
University of Michigan Rogel Cancer Center · Sites in United States
Ages 60–85 · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 12 · Phase 4 1
First in 1999; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is close to the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 34 across the 36 interventional studies, 68 across the 11 observational. Of the 40 that completed or were terminated, 14 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Michigan Rogel Cancer Center is the lead sponsor of 325 studies on the registry; 49 are open to participants now.
Of its 46 completed or terminated interventional studies of FDA-regulated products, 31 (67%) have results posted.
5 of the studies in Breast Neoplasms by University of Michigan Rogel Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05183126University of Michigan Rogel Cancer CenterPharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer | 2026-11 |
| NCT06100263University of Michigan Rogel Cancer CenterBreast Cancer Resiliency Through Exercise Program (B-REP) | 2026-12 |
| NCT05996107University of Michigan Rogel Cancer CenterStudy of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer | 2027-02 |
| NCT06915168University of Michigan Rogel Cancer CenterCIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer | 2027-03 |
| NCT07291414University of Michigan Rogel Cancer CenterA Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients | 2027-03-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 48 studies in Breast Neoplasms by University of Michigan Rogel Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study will use a cross-sectional study design with a follow-up 2-arm randomized controlled trial with that has assessments at baseline, post-intervention (i.e., Week 12), and 3-months post-intervention (i.e., Week 24). The 2 arms are the 12-week intervention and waitlist control among 30 Black breast cancer survivors
14AUG2025- The sample size was updated, and the questionnaire was split into 2 questionnaires, as a planned solution in response to a low accrual
28OCT2025- Amendment was processed to update design and intervention items. The exercise threshold was changed from a 1-repeition maximum (1RM) to a 5-repeptition maximum (5RM). Since the intervention includes functional exercises, so we elected to use a functional strength (5RM) outcome rather than a maximal strength outcome (1RM) to better align with the intervention. The control condition was changed to a waitlist design. A waitlist control is more engaging, and there is a higher likelihood of retaining control participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Women will be eligible if they meet the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The individualized program is based on participants' baseline 5-repetition maximum muscular strength assessment and is aligned with current cancer-specific exercise recommendations. The resistance program will follow the FITT principle (frequency, intensity, time, and type): Frequency. Participants will aim for 3 resistance exercise sessions per week. Intensity. Resistance exercise intensity will have a schedule for increased progression by both load via increased weight and volume via increased repetitions and sets. If participants are not able to increase resistance loads as scheduled, they will remain at their current load and volume until the next scheduled increase. 50% of 5-repetition maximum for upper and lower body. 3 sets of 8 to 12 repetitions. 60% of 5-repetition maximum for upper and lower body. 3 sets of 8 to 12 repetitions. 70% of 5-repetition maximum for upper and lower body. 4 sets of 8 to 12 repetitions.
Other: Individualized exercise program
Participants randomized to the waitlist control condition will be on a waiting list for 24 weeks. Participants in waitlist control condition will complete measures on the same schedule as intervention participants. After 24 weeks, participants will be offered to participate in the online sessions with an exercise trainer using Zoom twice per week for 12- weeks. The sessions will be 30 to 45minutes in length.
Other: Control Arm
guided exercise program for 12 weeks
Control Arm Waiting List for 24 weeks, then offered a guided exercise program for 12 weeks
Feasibility of the exercise program (Retention)
Percent of patients that complete the intervention
Time frame: up to 24 weeks after start of intervention
Feasibility of the exercise program (Adherence)
Percent of patients that complete the exercise sessions
Time frame: 12 weeks after start of intervention
Feasibility of the exercise program (fidelity)
Upon completion of the trial, a random sample of 10 recorded sessions will be analyzed for fidelity. Research staff who did not conduct the intervention will use a "fidelity checklist" of specific exercises and intervention characteristics (e.g., allowing time for questions, cueing for proper posture and form, etc.) required for each exercise session..
Time frame: 12 weeks after start of intervention
Satisfaction of program
14-item scale measuring ease of use, convenience, engagement, enjoyment, and privacy elements of the intervention.
Time frame: up to 24 weeks after start of intervention
Affective attitude
36-item scale assessing views, attitude, and experiences in exercise87
Time frame: up to 24 weeks after start of intervention
Perceived burden
Single item, "Now that you've completed this part of the study, how burdensome or difficult did you find the experience. Select the response that best represents your experience." (1= Very burdensome to 5= Not too burdensome.)
Time frame: up to 24 weeks after start of intervention
Outcome expectation
15-item scale assessing physical, social, and self-evaluative outcomes of exercise
Time frame: up to 24 weeks after start of intervention
Plan to share: No
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 31 months is close to that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Michigan Rogel Cancer Center →